miR-29b inhibitor

miR-29b inhibitors are a class of RNA-based therapeutic candidates, typically antisense oligonucleotides or antagomirs, designed to selectively bind and neutralize microRNA-29b. In the context of pulmonary hypertension (PH), miR-29b is upregulated under hypoxic conditions, where it suppresses the expression of the voltage-gated potassium channel Kv1.5 and activates the STIM1/Orai1-mediated calcium signaling axis. This molecular shift promotes the pathological proliferation and survival of pulmonary arterial smooth muscle cells (PASMCs), contributing to vascular remodeling. By inhibiting miR-29b, these agents aim to restore Kv1.5 expression and normalize intracellular calcium homeostasis, potentially attenuating the progression of hypoxia-induced PH. Research into miR-29b inhibition is currently in the preclinical stage, with studies supported by institutions such as the University of Minnesota and the American Heart Association.

Other names

antagomir-29bantagomir29bantagomir 29banti-miR-29banti-miR29banti-miR 29bmiR-29b antagomirmiR29b antagomirmiR 29b antagomir